Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 29

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 29
---
, and an aggregate of 1,261,896,210 shares of Common Stock would become issuable upon the exercise of the Series B Warrants, with an aggregate of 1,542,317,700 shares of Common Stock issuable upon exercise of the Warrants, and the ownership interest of our existing stockholders, other than the holders of the Warrants whose ownership interests would materially increase, would be correspondingly diluted by approximately 99%.

<div align='center'>16</div>

#### TABLE OF CONTENTS
The sale into the public market of these shares could materially and adversely affect the market price of our Common Stock.

#### Interest of Certain Persons in this Proposal
No director or executive officer has any substantial interest, direct or indirect, by security holdings or otherwise, in this Proposal that is not shared by all of our other stockholders.

#### Vote required
Approval of Proposal No. 2 requires the affirmative vote of a majority of the Common Stock having voting power present, virtually or by proxy. Abstentions are considered shares present and entitled to vote and thus will have the effect of a vote “AGAINST” this proposal. Broker non-votes will have no effect on the results of this vote.

Holders of the Warrants that were purchased in the Private Placement, shall not be entitled to vote those shares purchased in that offering on Proposal 2 (the Issuance Proposal). Holders that owned shares prior to the Private Placement, however, shall be entitled to vote those shares on Proposal 2.

#### Board Recommendation
**OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THIS PROPOSAL NO. 2 TO AUTHORIZE, FOR PURPOSES OF COMPLYING WITH NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF THE WARRANTS AND SHARES OF COMMON STOCK UNDERLYING THE WARRANTS AND CERTAIN PROVISIONS OF THE WARRANTS.**

<div align='center'>17</div>

TABLE OF CONTENTS

PROPOSAL 3: THE AUTHORIZED COMMON STOCK INCREASE Introduction Our Board has unanimously approved and declared advisable and is recommending that our stockholders approve and adopt a proposed amendment to our Certificate of Incorporation, in substantially the form attached hereto as Annex B, to increase the number of authorized shares of Common Stock from 100,000,000 to 2,000,000,000 shares of Common Stock. The proposed form of Certificate of Amendment to the Certificate of Incorporation to effect the increase in